- $5.10m
- -$4.98m
- $1.20m
NASDAQ RESUMED AT 06:00 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:55 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Longeveron Announces 1-For-10 Reverse Stock Split
Longeveron Q2 net loss widens on higher legal, clinical trial costs
Brief: Longeveron Q2 EPS USD -0.19
Brief: Longeveron Names Marie Washburn As Chief Financial Officer
Brief: Longeveron - On June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026 - SEC Filing
Longeveron Q1 revenue rises, beats analyst estimates
Brief: Longeveron Q1 EPS USD -0.19
Brief: Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Brief: Longeveron announces constructive Type C meeting with U.S. FDA ahead of data readout for ELPIS II Phase 2b clinical trial evaluating treatment for Hypoplastic Left Heart Syndrome
Brief: Longeveron Inc - Repaid Executives For Compensation Reductions Following Financing - SEC Filing
Brief: Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron
Longeveron rises as it wins China patent for stem cell test
Brief: Longeveron Granted U.S. Patent For Method Of Treating Female Sexual Dysfunction